Haleon plc Net Assets
Haleon plc net assets. Based on the latest financial reports, Haleon plc (HLN) has net assets worth $16.34 Billion USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.38 Billion) and total liabilities ($16.04 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Haleon plc (HLN) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.34 Billion |
| % of Total Assets | 50.46% |
| Annual Growth Rate | -8.15% |
| 5-Year Change | -37.86% |
| 10-Year Change | N/A |
| Growth Volatility | 14.05 |
Net Assets of Haleon plc (2019–2025)
Net assets of Haleon plc from 2019 to 2025. This chart illustrates how Haleon plc's net assets have evolved over time, based on quarterly financial data. See HLN equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Haleon plc (2019–2025)
The table below shows the annual net assets of Haleon plc from 2019 to 2025. For live market cap and overall valuation, see Haleon plc (HLN) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $16.46 Billion | +1.42% |
| 2024-12-31 | $16.22 Billion | -3.02% |
| 2023-12-31 | $16.73 Billion | +1.65% |
| 2022-12-31 | $16.46 Billion | -37.85% |
| 2021-12-31 | $26.48 Billion | +0.98% |
| 2020-12-31 | $26.22 Billion | -4.34% |
| 2019-12-31 | $27.41 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Haleon plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 215.9% over the analyzed period, indicating profitable operations and earnings retention.
Haleon plc Net Assets Breakdown (December 2025)
Haleon plc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $16.13 Billion | 98.39% |
| Common Stock | $89.84 Million | 0.55% |
| Other Comprehensive Income | $335.41 Million | 2.05% |
| Total Equity | $16.40 Billion | 100.00% |
Haleon plc Competitors by Market Cap
The table below lists competitors of Haleon plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD
|
$40.32 Billion |
|
Ameriprise Financial Inc
NYSE:AMP
|
$40.38 Billion |
|
Itaú Unibanco Holding S.A
F:BVXB
|
$40.43 Billion |
|
Goodman Group
AU:GMG
|
$40.48 Billion |
|
AngloGold Ashanti Ltd
JSE:ANG
|
$40.14 Billion |
|
Bank of Communications Co. Ltd
F:C4C
|
$40.12 Billion |
|
CSL LTD SPON.ADR 2
F:CSJA
|
$40.06 Billion |
|
JD.com Inc Adr
NASDAQ:JD
|
$40.04 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Haleon plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,166,000,000 to 16,396,129,908, a change of 230,129,908 (1.4%).
- Net income of 1,630,468,421 contributed positively to equity growth.
- Dividend payments of 598,588,286 reduced retained earnings.
- Share repurchases of 639,667,874 reduced equity.
- Other comprehensive income decreased equity by 426,049,785.
- Other factors increased equity by 263,967,432.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.63 Billion | +9.94% |
| Dividends Paid | $598.59 Million | -3.65% |
| Share Repurchases | $639.67 Million | -3.9% |
| Other Comprehensive Income | $-426.05 Million | -2.6% |
| Other Changes | $263.97 Million | +1.61% |
| Total Change | $- | 1.42% |
Book Value vs Market Value Analysis
This analysis compares Haleon plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.54x to 2.51x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $5.92 | $9.14 | x |
| 2020-12-31 | $5.66 | $9.14 | x |
| 2021-12-31 | $5.71 | $9.14 | x |
| 2022-12-31 | $3.54 | $9.14 | x |
| 2023-12-31 | $3.59 | $9.14 | x |
| 2024-12-31 | $3.52 | $9.14 | x |
| 2025-12-31 | $3.64 | $9.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Haleon plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.94%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.78%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.99x
- Recent ROE (9.94%) is above the historical average (6.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 2.40% | 7.72% | 0.24x | 1.31x | $-2.08 Billion |
| 2020 | 4.38% | 11.58% | 0.29x | 1.31x | $-1.47 Billion |
| 2021 | 5.27% | 14.56% | 0.28x | 1.31x | $-1.25 Billion |
| 2022 | 6.49% | 9.76% | 0.31x | 2.13x | $-573.10 Million |
| 2023 | 6.32% | 9.28% | 0.33x | 2.05x | $-611.60 Million |
| 2024 | 8.92% | 12.84% | 0.33x | 2.12x | $-174.60 Million |
| 2025 | 9.94% | 14.78% | 0.34x | 1.99x | $-9.14 Million |
Industry Comparison
This section compares Haleon plc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $203,195,263
- Average return on equity (ROE) among peers: 107.35%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Haleon plc (HLN) | $16.34 Billion | 2.40% | 0.98x | $40.25 Billion |
| Aurora Cannabis Inc (ACB) | $1.56 Billion | 4.60% | 0.21x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $249.17 Million | -36.07% | 0.09x | $143.73 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $454.36K |
| Akebia Ther (AKBA) | $-49.19 Million | 0.00% | 0.00x | $107.50 Million |
| Alkermes Plc (ALKS) | $98.82 Million | -103.60% | 2.00x | $7.70 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $3.29 Billion |
| Amphastar P (AMPH) | $233.44 Million | 7.75% | 0.36x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $5.96 Million | 1208.40% | 615.85x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-175.94 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $143.47 Million | -7.58% | 0.33x | $194.72 Million |
About Haleon plc
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; an… Read more